PO.CL07.02 · 临床研究
Liquid biopsy-informed precision oncology clinical trial to evaluate the utility of ctDNA genomic profiling for therapy optimization in patients with advanced or metastatic solid tumors
该海报暂无可访问的完整资料
AACR 官方页面 ↗
作者与单位
摘要 Abstract
Background: Genomic profiling via liquid biopsies (LB) has advanced precision oncology decision-making; however, a major challenge is critically interpreting LB data to improve the selection and order of genotype-specific therapies.
Methods: We present updated results from the first planned analysis of an observational biomarker trial, aimed at assessing the clinical utility of serial LB in patients with advanced or metastatic solid tumors (NCT05585684). Primary endpoints assessed feasibility, prevalence of actionable alterations, and fraction of patients receiving genotype-matched therapies. Secondary endpoints encompassed progression-free survival (PFS), overall survival (OS), and concordance between LB and tumor next-generation sequencing (NGS). Serial LBs at baseline, early (1-3 weeks) on therapy, and at progression, employed a clinically validated 33-gene panel NGS assay (Labcorp Plasma Focus). Matched white blood cell (WBC) NGS was used to identify clonal hematopoiesis (CH)-derived variants. Mutation actionability was evaluated using a multi-resource programmatic approach, and levels of evidence (1-4) were assigned, followed by review at the Johns Hopkins Molecular Tumor Board (JH MTB).
Results: Among 50 patients, 45 baseline and 12 progression LBs were reviewed at MTB. JH MTB classified 72.5% (n=50) of baseline alterations as tumor-derived. In 19 patients with archival tissue NGS, 32 variants were detected in the baseline LB, of which 78.1% were also detected in tissue NGS. Furthermore, 23.2% (n=16) of LB alterations at baseline, 20.0% (n=6) early on-therapy, and 13.0% (n=3) at progression were CH derived. Upon MTB review, 29.2% variants at baseline, 21.9% at early on-therapy and 26.1% at progression were classified as actionable (58.8% level 1, 11.8% level 2, 11.8% level 3 and 17.6% level 4 evidence). Of 45 patients reviewed, 38 received therapeutic recommendations and 57.9% initiated recommended therapy. Patients treated with MTB recommended therapies had significantly longer median PFS and OS compared to those who received standard of care (p=0.027 and p=0.00062 respectively). MTB-recommended therapy selection was independently associated with PFS and OS, in multivariate analyses adjusting for clinical covariates including sex, smoking status, age, and prior lines of systemic therapy (p=0.043 and p=0.006, respectively). Subset of patients treated with genotype-matched MTB recommendations had significantly longer median PFS and OS compared to those who received standard of care (p=0.026 and p=0.0074 respectively).
Conclusion: Our findings emphasize the importance of precision oncology interventions driven by programmatic workflows within a multidisciplinary MTB, supported by comprehensive LB molecular information to guide therapy selection and improve patient outcomes.
利益披露 Disclosure
A. Jamali, None..
J. Wehr, None.
J. V. Canzoniero,
Foundation Medicine ).
Astra Zeneca Other, Honoraria.
Johns Hopkins University Patent.
Haystack Diagnostics ).
M. Fatteh, None..
K. Karaindrou, None..
M. Conroy, None..
I. Ziakas, None..
M. Sherief, None..
T. Wanchoo, None..
F. Too, None..
L. Scharpf, None..
R. Moges, None..
D. Petry, None..
K. Visvanathan, None.
E. Verner,
Labcorp Employment, Stock.
A. Greer,
Labcorp Employment, Stock.
K. Kreimeyer, None..
J. Spiker, None..
R. Karchin, None.
C. L. Hann,
Astra Zeneca ), Other, Consultant.
Daiichi Sankyo Europe GmbH ), Other, Consultant.
Genentech Other, Consultant.
Amgen ).
V. K. Lam,
GlaxoSmithKline ).
Astra Zeneca ), Other, Consultant.
Merck ).
Nuvalent ).
Bristol Myers Squibb ), Other, Consultant.
Iovance Biotherapeutics Other, Consultant, Data safety and monitoring board member.
Lilly Other, Consultant.
Takeda Other, Consultant.
Nuvation Bio Other, Consultant.
Guardant Health Other, Consultant.
Genentech/Roche Other, Consultant.
Pfizer Other, Consultant.
J. C. Murray,
Janssen (Johnson & Johnson) Other, Consultant.
Astra Zeneca Other, Consultant.
Curio Science Other, Honoraria.
Caris Life Sciences Other, Honoraria.
ION Oncology Practice Network Other, Honoraria.
Nebraska Oncology Society Other, Honoraria.
PRIME Other, Honoraria.
iTeos Therapeutics Other, Advisory board member.
Doximity Stock Option.
NIH/NCI ).
CDC ).
Maryland Cigarette Restitution Fund ).
Merck ).
J. Feliciano,
Astra Zeneca ), Other, Consultant.
Pfizer ).
Bristol Myers Squibb ).
Regeneron Other, Consultant.
Coherus Other, Consultant.
Eli Lilly Other, Consultant.
Genentech Other, Consultant.
Takeda Other, Consultant.
Janssen Other, Consultant.
Daiichi Sankyo Other, Consultant.
K. Marrone,
Astra Zeneca Other, Consultant, Honoraria.
Amgen Other, Consultant.
Janssen Other, COnsultant.
Mirati Therapeutics ), Other, Consultant.
Daiichi Sankyo/Lilly Other, Consultant.
Puma Biotechnology Other, Consultant.
Bristol Myers Squibb ).
J. R. Brahmer,
Astra Zeneca ), Other, Consultant.
Bristol Myers Squibb ).
RAPT Therapeutics Other, Consultant.
Mestag Other, Consultant.
GlaxoSmithKline Other, Consultant.
Amgen Other, Consultant.
Sanofi Aventis Other, Consultant.
Summit Therapeutics Other, Consultant.
Genentech Other, Consultant.
Beyer Other, Consultant.
Genmab Other, Data safety and monitoring board member.
M. Lin, None..
T. Botsis, None..
H. Wang, None.
M. Sausen,
Labcorp Employment, Stock.
C. D. Gocke, None..
R. Xian, None..
J. Tao, None.
V. K. Anagnostou,
Astra Zeneca ), Other, Advisory board member.
Bristol-Myers Squibb ).
Personal Genome Diagnostics/Labcorp ), Other, Honoraria.
Delfi Diagnostics ).
Neogenomics Other, Advisory board member.
Foundation Medicine Other, Honoraria.
Roche Other, Honoraria.
ThermoFisher Other, Honoraria.
Guardant Health Other, Honoraria.